(MEDHLP) Medhelp Care - Ratings and Ratios

Medhelp Care AB (ST:MEDHLP) is a Swedish software-as-a-service (SaaS) company that has developed a comprehensive health platform designed to support data-driven corporate health initiatives in Sweden and Denmark. By providing a suite of services including absence management, sickness absence statistics, healthcare advice, and rehabilitation support, Medhelp Care is positioned to capitalize on the growing demand for digital health solutions.

The companys platform is likely to benefit from the increasing trend of companies adopting digital health technologies to improve employee wellbeing, reduce absenteeism, and enhance overall productivity. With its headquarters in Stockholm, Sweden, and a history dating back to 1999, Medhelp Care has established itself as a pioneer in the Nordic regions health technology sector. For more information, you can visit their website at https://www.medhelp.se.

From a market perspective, Medhelp Cares common stock (MEDHLP) is classified under the Health Care Technology sub-industry, which is expected to experience significant growth driven by the increasing adoption of digital health technologies. With a market capitalization of 105.30M SEK, the company has a relatively modest size, which could indicate potential for expansion.

Analyzing the available and , we can observe that the stock has shown a positive trend, with its last price at 4.04 SEK, above its 20-day, 50-day, and 200-day simple moving averages (SMA). The Average True Range (ATR) indicates a moderate level of volatility. Considering the , the stocks P/E ratio is relatively high at 49.43, and the forward P/E is 54.05, suggesting high growth expectations. The Return on Equity (RoE) stands at 7.80%, indicating a decent level of profitability.

Based on the available data, a forecast for Medhelp Care AB could be constructed by combining the insights from both technical and fundamental analysis. Given the positive trend indicated by the SMA and the relatively high P/E ratio, it is likely that the stock will continue to experience growth, driven by the increasing demand for health technology solutions. However, the high P/E ratio also suggests that the stock may be overvalued to some extent, which could limit its upside potential. Therefore, a reasonable forecast would be a gradual increase in the stock price, potentially reaching 4.50 SEK in the short term, driven by the companys strong growth prospects in the health technology sector.